| 1 |
NCT02695498 |
Recruiting |
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines |
|
- Other: Mindfulness Based Stress Reduction
- Other: Migraine/stress Education
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in frequency of migraine days from baseline
- Change in migraine duration from baseline
- Change in migraine severity-pain intensity from baseline
- (and 22 more...)
|
98 |
All |
18 Years and older (Adult, Senior) |
NCT02695498 |
K23AT008406 |
|
March 2016 |
May 2019 |
June 2019 |
March 1, 2016 |
November 6, 2017 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 2 |
NCT03381924 |
Completed |
Educational Intervention in Patients With Migraine |
|
- Other: Educational programme
- Other: Routine clinical practice
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine-related disability given by the MIDAS score
- Intensity and frequency of the pain
- Degree to which activities of daily life were limited by migraine
- costs associated with migraine-related treatment
|
116 |
All |
Child, Adult, Senior |
NCT03381924 |
MIGRAINE01 |
M01 |
August 1, 2013 |
May 30, 2016 |
May 30, 2016 |
December 22, 2017 |
December 22, 2017 |
|
- Iñaki Aguirrezabal Bazterrica
Vitoria-gasteiz, Alava, Spain
|
| 3 |
NCT03395457 |
Not yet recruiting |
Tertiary Care With or Without Manual Therapy for Chronic Migraine |
|
- Drug: Care as usual
- Other: Manual Therapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in migraine-related disability
- Change in Migraine Specific Quality of Life Questionnaire Score (MSQoL 2.1)
- Headache Frequency
|
100 |
Female |
18 Years and older (Adult, Senior) |
NCT03395457 |
Bournemouth 228901 |
|
March 2018 |
July 2018 |
July 2018 |
January 10, 2018 |
January 10, 2018 |
|
|
| 4 |
NCT01294046 |
Completed
Has Results |
Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches |
|
- Device: Deep Brain Stimulation of SPG for Migraine
|
Interventional |
Not Applicable |
- The Cleveland Clinic
- Autonomic Technologies, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine Relief at 2 Hours Post Stimulation
- Migraine Free at 2 Hours
- Pain Free at 2 Hours Post Stimulation
- (and 7 more...)
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT01294046 |
IDE Number : G100007 |
|
March 2011 |
March 2014 |
March 2014 |
February 11, 2011 |
April 14, 2017 |
March 7, 2017 |
- Cleveland Clinic
Cleveland, Ohio, United States
|
| 5 |
NCT02703129 |
Completed |
Nutritional Intervention in Migraine |
|
- Other: Nutritional intervention
|
Interventional |
Not Applicable |
- Federal University of Minas Gerais
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in clinical parameters of migraine patients by nutritional intervention in the last month.
- Change in clinical parameters of migraine patients by nutritional intervention in the last three month.
- Change in diet quality of migraine patients by nutritional intervention assessed with the Brazilian Healthy Eating Index - Revised (BHEI-R)
- Change in depressive symptoms in migraine patients by nutritional intervention assessed with the Beck Depression Inventory (BDI)
|
52 |
|
Child, Adult, Senior |
NCT02703129 |
CAAE 0311.0.203.000-11 |
|
January 2010 |
December 2012 |
December 2012 |
March 9, 2016 |
March 9, 2016 |
|
- Ambulatório Bias Fortes
Belo Horizonte, Minas Gerais, Brazil
|
| 6 |
NCT03026101 |
Recruiting |
Understanding the Pathophysiology of Migraine Pain |
- Migraine Disorders
- Migraine, Classic
- Migraine Without Aura
|
|
Interventional |
Not Applicable |
- Montefiore Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Migraine
- Migraine log pre-procedure: severity measure
- Migraine log pre-procedure: frequency measure
- (and 17 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03026101 |
MontefioreMigraine |
|
January 2017 |
January 2019 |
June 2019 |
January 20, 2017 |
March 23, 2018 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
| 7 |
NCT02570633 |
Unknown † |
Ginger Capsules for the Prophylactic Treatment of Migraine |
|
- Other: Extract of ginger
- Other: Cellulose
|
Interventional |
Not Applicable |
- Federal University of Minas Gerais
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in the frequency of migraine attacks.
- Change in migraine impact in the last month.
- Change in migraine impact in the last three months.
- Changes in the serum levels of biomarkers.
|
104 |
All |
18 Years to 60 Years (Adult) |
NCT02570633 |
CAAE 28236814.3.0000.5149 |
|
July 2014 |
September 2016 |
January 2017 |
October 7, 2015 |
March 25, 2016 |
|
- Ambulatório Bias Fortes
Belo Horizonte, Minas Gerais, Brazil
|
| 8 |
NCT03004313 |
Completed |
Structural and Molecular Neuroplasticity in Migraine |
|
- Procedure: Pet Scan
- Procedure: MRI scan
- Procedure: Quantitative Sensory Testing (QST)
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Level of mu-opioid receptor binding potential in the brain of episodic migraineurs during and outside the headache attack and compared to healthy controls.
- Correlation of migraine attack severity in migraineurs with mu-opioid receptor binding potential
|
32 |
All |
18 Years to 45 Years (Adult) |
NCT03004313 |
HUM00027383 |
|
January 2011 |
October 2014 |
October 2014 |
December 28, 2016 |
November 24, 2017 |
|
- University of Michigan - Michigan Center for Oral Health Research
Ann Arbor, Michigan, United States
|
| 9 |
NCT02443519 |
Recruiting |
Bronx MBCT-Migraine |
|
- Behavioral: MBCT for Migraine
|
Interventional |
Not Applicable |
- Albert Einstein College of Medicine, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment
- Headache-Related Disability Index
- Headache Days (over course of 1 month)
- (and 9 more...)
|
80 |
All |
18 Years to 65 Years (Adult) |
NCT02443519 |
2015-4684 |
BMBCT-M |
May 2015 |
September 2018 |
July 2019 |
May 14, 2015 |
January 16, 2018 |
|
- Yeshiva University
Bronx, New York, United States
|
| 10 |
NCT03220113 |
Recruiting |
Treatment of Chronic Migraine Headaches. |
- Chronic Migraine Without Aura, Intractable
- Migraine With Typical Aura
- Migraine Disorders
|
- Combination Product: Dexamethasone, Lidocaine, Thiamine cohort
|
Interventional |
Phase 1
Phase 2 |
- Corona Doctors Medical Clinics, Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of the safety to the De-Novo treatment formula in study patients
- Assessment of the clinical response to the De-Novo treatment formula in study patients consisting of a lone composite measure
|
100 |
All |
10 Years to 90 Years (Child, Adult, Senior) |
NCT03220113 |
2017/05/1 |
Migraine |
July 1, 2017 |
July 1, 2018 |
July 1, 2019 |
July 18, 2017 |
April 4, 2018 |
|
- Corona Doctors Medical Clinics Inc
Corona, California, United States
|
| 11 |
NCT03487978 |
Enrolling by invitation
New |
Longitudinal Changes of Brain Functional Connectivity in Migraine |
|
- Diagnostic Test: resting-state functional MRI
|
Observational |
|
- Samsung Medical Center
- National Research Foundation of Korea
- Sungkyunkwan University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Core fMRI features for migraine brain
- Candidate fMRI features for migraine
- Dynamic fMRI features for disease severity
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03487978 |
2017-03-113 |
|
July 24, 2017 |
April 30, 2018 |
February 28, 2020 |
April 4, 2018 |
April 20, 2018 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 12 |
NCT02108678 |
Completed |
One-Day Intervention for Depression and Impairment in Migraine Patients |
|
- Behavioral: ACT-ME
- Behavioral: Migraine Education Only
|
Interventional |
Not Applicable |
- Baylor College of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HRSD
- SCID-IV
- WHO-DAS-II
- (and 2 more...)
|
104 |
All |
18 Years to 65 Years (Adult) |
NCT02108678 |
201301712 |
ACT |
September 2013 |
September 2017 |
September 2017 |
April 9, 2014 |
December 22, 2017 |
|
- University of Iowa Carver College of Medicine Department of Psychiatry
Iowa City, Iowa, United States
|
| 13 |
NCT02945839 |
Not yet recruiting |
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department |
|
- Drug: Preventative Medication (PM)
- Behavioral: Enhanced Usual Care
- Behavioral: PMR (progressive muscle relaxation therapy)
|
Interventional |
Phase 4 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment Scale (MIDAS) at 3 Months and Baseline
- Perceived Stress Scale (PSS)
- Number of days/week treated with acute medications
- Number of drug administrations/week for acute medications
|
90 |
All |
18 Years to 64 Years (Adult) |
NCT02945839 |
16-00548 |
|
April 2018 |
December 2018 |
December 2018 |
October 26, 2016 |
January 23, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
| 14 |
NCT03361423 |
Recruiting |
Evaluation of a Novel Device for Treatment of Migraine Headache |
- Migraine Without Aura
- Migraine With Aura
|
- Device: Nerivio Migra-1 active device
- Device: Nerivio Migra-1 Sham device
|
Interventional |
Not Applicable |
- Theranica
- Rambam Health Care Campus
- Northwell Health
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of reduction of migraine headache post 2 hours from treatment
- Percentage of reduction of most bothersome migraine-associated symptom (MBS) relief post 2 hours treatment
- Percentage of reduced Migraine Headache AND MBS Relief post 2 hours post tresatment
- Percentage of pain disappearance 2 hours post treatment
|
270 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03361423 |
TCH003 |
|
December 17, 2017 |
June 30, 2018 |
August 30, 2018 |
December 4, 2017 |
February 19, 2018 |
|
- Hartford Headache Center
Hartford, Connecticut, United States - Mercy Hospital
Saint Louis, Missouri, United States - Northwell Health, Inc
New York, New York, United States - (and 4 more...)
|
| 15 |
NCT03166046 |
Recruiting |
Migraine Prevention Using ActiPatch |
|
- Device: Pulsed Shortwave Therapy
- Device: Placebo Pulsed Shortwave therapy
|
Interventional |
Not Applicable |
- BioElectronics Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine frequency
- Migraine duration
- Migraine intensity measured with Visual Analogue Pain Score
- Headache disability measured with Headache Impact Test
|
80 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03166046 |
SAIRB-17-0021 |
PSWT |
June 1, 2017 |
April 21, 2018 |
April 30, 2018 |
May 24, 2017 |
March 22, 2018 |
|
- Eppley Group
Indianapolis, Indiana, United States
|
| 16 |
NCT01803984 |
Unknown † |
MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction |
|
- Device: MRI
- Device: EndoPAT
- Other: Neuropsychological battery
|
Observational |
|
- University Hospital, Bordeaux
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Differences in magnetic resonance imaging (MRI) between migraine without aura and migraine with aura patients (frequency of hyperintensities, white matter lesions....)
- Differences in the Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) between migraine without aura and migraine with aura patients.
- Differences in the Reactive Hyperemia Index (RHI) and the Augmentation Index (AI) between migraine without aura and migraine with aura patients
- Correlation between MRI and Total Score of RBANS with RHI / AI (endothelial function) between migraine groups.
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT01803984 |
CHUBX 2012/19 |
MIBRAIN |
March 2013 |
June 2015 |
June 2015 |
March 4, 2013 |
January 14, 2015 |
|
- Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
|
| 17 |
NCT03152305 |
Recruiting |
Intracranial Pressure During Migraine |
|
- Other: Intracranial pressure variations
|
Observational |
|
- University Hospital, Clermont-Ferrand
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Intracranial pressure variations
- Relationships between ICP variations and clinical parameters
- Relationships between ICP variations and pain relief
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT03152305 |
CHU-331
2014-A00042-45 |
MigICP |
July 21, 2014 |
May 2017 |
July 2018 |
May 15, 2017 |
May 15, 2017 |
|
- CHU Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
|
| 18 |
NCT01899040 |
Completed |
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache |
- Migraine Headache, Episodic
|
- Device: neuromodulation for episodic migraine headache
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of monthly migraine headache days
- Number of monthly migraine headache days (reduction by by 50% or more)
- Total monthly pain score
- (and 4 more...)
|
81 |
All |
18 Years to 65 Years (Adult) |
NCT01899040 |
SNS-MIG-01 |
|
August 2013 |
May 2016 |
June 2016 |
July 15, 2013 |
October 18, 2016 |
|
- Naval Medical Center
San Diego, California, United States - Michigan Headache and Neurological Institute
Ann Arbor, Michigan, United States - Carolina Headache Institute
Chapel Hill, North Carolina, United States - (and 3 more...)
|
| 19 |
NCT03097536 |
Recruiting |
Migraine and Homeostasis:What Can we Learn From Glucose |
|
|
Interventional |
Not Applicable |
- Beth Israel Deaconess Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The difference in blood glucose on days with migraine compared to blood glucose on days without migraine
- The primary outcome is the change in pain score from the time of pain plateau to the pain score at 120 minutes as measured by a visual analogue scale.
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT03097536 |
2015P000419 |
|
March 2016 |
June 2018 |
September 2018 |
March 31, 2017 |
April 5, 2017 |
|
- Beth Israel Deaconess Medial Center
Boston, Massachusetts, United States
|
| 20 |
NCT00904150 |
Completed
Has Results |
Study of the Molecular Genetics of Menstrual Migraine |
|
|
Observational |
|
- The City of London Migraine Clinic
- Griffith University
- The City of London Migraine Clinic
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Progesterone Receptor Gene Polymorphism PROGINS in Women With Menstrual Migraine and Women Without Migraine
- Estrogen Receptor 1 G594a Polymorphism in Women With Menstrual Migraine and Women Without Migraine
- Estrogen Receptor 1 C325G Polymorphism in Women With Menstrual Migraine and Women Without Migraine
- (and 4 more...)
|
585 |
Female |
18 Years and older (Adult, Senior) |
NCT00904150 |
COLMC-GEN-2007
REC Ref: 07/H0703/107
Proposal # 36470
Grant Application 2007/03 |
|
November 2007 |
August 2013 |
August 2013 |
May 19, 2009 |
February 24, 2014 |
February 24, 2014 |
- The City of London Migraine Clinic
London, United Kingdom
|
| 21 |
NCT01476930 |
Completed |
Cupping and Serkangabin Versus Conventional Migraine Treatment |
|
- Procedure: cupping and serkangabin syrup
- Drug: conventional migraine drug treatment
|
Interventional |
Phase 4 |
- Birjand University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- frequency of migraine attacks per week
- severity of migraine attacks
- duration of migraine attacks
- frequency of migraine attacks
|
391 |
All |
15 Years to 50 Years (Child, Adult) |
NCT01476930 |
n231
n231hej |
|
June 2008 |
September 2009 |
October 2011 |
November 22, 2011 |
November 24, 2014 |
|
- Birjand University of Medical Sciences,Valiasr Hospital
Birjand, South Khorasan, Iran, Islamic Republic of
|
| 22 |
NCT01687660 |
Unknown † |
Acupuncture for Migraine Prophylaxis |
- Migraine Without Aura
- Unilateral Headache
|
|
Interventional |
Phase 2
Phase 3 |
- 973-2
- Hunan University of Traditional Chinese Medicine
- Chongqing Medical University
- Chengdu University of Traditional Chinese Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- frequency of migraine attacks
- headache severity
|
249 |
All |
18 Years to 65 Years (Adult) |
NCT01687660 |
2012CB518501-2 |
AMP |
September 2012 |
September 2014 |
September 2014 |
September 19, 2012 |
October 23, 2013 |
|
- Chengdu University of TCM
Chengdu, Sichuan, China
|
| 23 |
NCT01653340 |
Completed |
A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine |
- Refractory Chronic Migraine
|
- Device: Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine
|
Interventional |
Not Applicable |
- University of Roma La Sapienza
- Guy's and St Thomas' NHS Foundation Trust
- King's College Hospital NHS Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency in headache days
- Frequency in migraine days
- Frequency of moderate/severe headache days
- (and 8 more...)
|
18 |
All |
18 Years to 65 Years (Adult) |
NCT01653340 |
CE100112
2012-002005-22 |
rCM HF-SCS |
May 2012 |
February 2014 |
February 2014 |
July 31, 2012 |
February 19, 2014 |
|
- Sant'Andrea Hospital
Roma, RM, Italy
|
| 24 |
NCT03453203 |
Not yet recruiting |
Treatment of Cervical Pain in Chronic Migraine |
|
- Other: Osteopathic Manipulative Treatment Using Counterstrain
|
Interventional |
Not Applicable |
- University Hospitals Cleveland Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Treatment of Cervical Pain in Chronic Migraine
|
30 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03453203 |
UHClevelandMC1 |
|
April 29, 2018 |
December 29, 2018 |
December 29, 2018 |
March 5, 2018 |
March 7, 2018 |
|
|
| 25 |
NCT02748577 |
Recruiting |
Pain Processing in Adults With Migraines |
|
- Other: Questionnaires
- Other: Quantitative Sensory Testing (QST) Pain Measurements
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Heat Pain Intensity coefficient and intercept from stimulus response curve
- Heat Pain Unpleasantness coefficient and intercept from stimulus response curve
- Pain Catastophizing score
- (and 13 more...)
|
98 |
All |
18 Years and older (Adult, Senior) |
NCT02748577 |
IRB00027845 |
|
January 2016 |
July 2020 |
July 2020 |
April 22, 2016 |
October 24, 2017 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 26 |
NCT03175263 |
Completed |
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain |
|
|
Observational |
|
- University Hospital, Limoges
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- frequency of headache days
- the proportion of patients with a ≥ 70% decrease in headache day frequency
- the decrease in triptan consumption
- the assessment of patient satisfaction
|
57 |
All |
18 Years and older (Adult, Senior) |
NCT03175263 |
I17022 |
|
September 1, 2008 |
December 30, 2015 |
December 30, 2015 |
June 5, 2017 |
June 5, 2017 |
|
|
| 27 |
NCT01197196 |
Active, not recruiting |
Behavioral Weight Loss as a Treatment for Migraine in Obese Women |
|
- Behavioral: Behavioral Weight Loss Intervention
- Other: Migraine Education
|
Interventional |
Not Applicable |
- The Miriam Hospital
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the number of migraine headache days
- Change in body weight
- Changes in serum inflammatory markers (C-reactive protein, Interleukin-6)
- (and 3 more...)
|
112 |
Female |
18 Years to 50 Years (Adult) |
NCT01197196 |
0068-10
R01NS077925-01A1 |
|
July 2012 |
June 2017 |
June 2017 |
September 9, 2010 |
December 21, 2016 |
|
- The Miriam Hospital Weight Control and Diabetes Research Center
Providence, Rhode Island, United States
|
| 28 |
NCT03333109 |
Recruiting |
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients |
|
- Biological: Erenumab
- Other: Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from baseline in monthly migraine days at the last month (Month 3) of the double-blind treatment period (DBTP)
- Achievement of at least a 50% reduction from baseline in monthly migraine days at Month 3
- Change from Baseline in acute migraine-specific medication treatment days at Month 3
- Change from Baseline in headache impact scores as measured by the HIT-6 at Month 3
|
880 |
All |
18 Years to 65 Years (Adult) |
NCT03333109 |
CAMG334A2302 |
EMPOwER |
February 8, 2018 |
February 7, 2020 |
February 7, 2020 |
November 6, 2017 |
February 15, 2018 |
|
- Novartis Investigative Site
Beirut, Lebanon
|
| 29 |
NCT02969642 |
Recruiting |
Study of Low-level Laser Therapy in the Acute Treatment of Migraine |
|
- Device: Argus Migraine Treatment device
|
Interventional |
Phase 2 |
- The San Francisco Clinical Research Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Differences between treatment groups in pain free rates at 2 hours post treatment.
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02969642 |
AP 1001 |
|
March 2016 |
May 2017 |
July 2017 |
November 21, 2016 |
December 2, 2016 |
|
- San Francisco Clinical Research Center
San Francisco, California, United States
|
| 30 |
NCT01010711 |
Unknown † |
Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents |
|
- Dietary Supplement: Migra 3
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of days with headache before and after 12 weeks of daily treatment with a migraine specific dietary supplement
- frequency, duration and intensity of the migraine
|
76 |
All |
8 Years to 17 Years (Child) |
NCT01010711 |
TOM-DS-CH-1 |
|
November 2009 |
December 2010 |
April 2011 |
November 10, 2009 |
February 2, 2010 |
|
- Universiätsklinikum Essen Neurologische Klinik, Westdeutsches Kopfschmerzzentrum, Hufelandstr.26,
Essen, Nordrhein-Westfalen, Germany - Migräne und Kopfschmerzklinik Königstein
Königstein Im Taunus, Germany
|
| 31 |
NCT01916395 |
Completed |
Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache |
|
- Drug: sumatriptan and Treximet
|
Observational |
|
- Gary E. Ruoff, M.D.
- GlaxoSmithKline
- Westside Family Medical Center, P.C.
|
Other / Industry |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- The outcome will be to determine whether inflammatory markers are reduced in patients having a migraine when treated with Imitrex 100mg or Treximet.
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT01916395 |
GR10 |
|
December 2009 |
December 2010 |
July 2011 |
August 5, 2013 |
August 5, 2013 |
|
- Westside Family Medical Center, PC
Kalamazoo, Michigan, United States
|
| 32 |
NCT02169830 |
Recruiting |
Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine |
|
- Drug: nortriptyline
- Drug: Topiramate
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- evaluate the comparative effectiveness of migraine diet, nortriptyline and topiramate
|
100 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02169830 |
24482_ Vest_Migraine |
|
June 2014 |
July 2018 |
September 2018 |
June 23, 2014 |
October 25, 2017 |
|
- Saint Louis University
Saint Louis, Missouri, United States
|
| 33 |
NCT02315833 |
Recruiting |
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients |
|
- Drug: Acetium
- Drug: Placebo
|
Interventional |
Not Applicable |
- Biohit Oyj
- The Finnish Funding Agency for Technology and Innovation (TEKES)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of migraine attacks (NMA) per evaluation interval
- Number of migraine days (NMD) per evaluation period
|
200 |
All |
18 Years to 65 Years (Adult) |
NCT02315833 |
AC-MIGPREV-1 |
|
June 2014 |
December 2017 |
December 2017 |
December 12, 2014 |
June 23, 2017 |
|
- Terveystalo, Kamppi
Helsinki, Finland - Lääkärikeskus Aava, Helsingin Päänsärkykeskus Oy
Helsinki, Finland - Terveystalo, Jyväskylä
Jyväskylä, Finland - (and 2 more...)
|
| 34 |
NCT02708797 |
Completed |
Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura. |
|
- Other: Magnetic resonance imaging
- Other: Transcranial Doppler
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Correlation between the density of the pontine grey matter evaluated with resonance magnetic imaging, and cerebral autoregulation measured with Transcranial Doppler in migraine with aura patients and controls.
- Comparison of brainstem grey matter density between migraine with aura patients and controls with magnetic resonance imaging
- Comparison of cerebral autoregulation between migraine with aura patients and controls with Transcranial Doppler
- (and 6 more...)
|
46 |
All |
30 Years to 55 Years (Adult) |
NCT02708797 |
RC31/15/7815
2015-A01982-47 |
MINOTAURE |
May 2016 |
April 2017 |
April 2017 |
March 15, 2016 |
February 6, 2018 |
|
- CHU Toulouse
Toulouse, France
|
| 35 |
NCT02630459 |
Active, not recruiting |
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention |
|
- Drug: AMG 334 Dose Level 1
- Drug: Placebo
- Drug: AMG 334 Dose Level 2
- Drug: AMG 334 Dose Level 3
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in mean monthly migraine days
- Proportion of subjects with at least a 50% reduction from baseline in mean monthly migraine days
- Change from baseline in acute migraine-specific medication treatment days
|
475 |
All |
20 Years to 65 Years (Adult) |
NCT02630459 |
20120309 |
|
January 6, 2016 |
September 25, 2017 |
June 3, 2019 |
December 15, 2015 |
December 6, 2017 |
|
- Research Site
Kamogawa-shi, Chiba, Japan - Research Site
Saijo-shi, Ehime, Japan - Research Site
Ota-shi, Gunma, Japan - (and 41 more...)
|
| 36 |
NCT03108469 |
Recruiting |
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine |
|
- Drug: IONIS-PKKRx (ISIS 546254)
- Other: Placebo
|
Interventional |
Phase 2 |
- Smith, Timothy R., M.D.
- Clinvest Research, LLC
- Ionis Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Comparison of Adverse Events
- Change in Migraine Days
- Change in Headache Severity
- (and 6 more...)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT03108469 |
15-001IS |
|
August 1, 2017 |
December 31, 2018 |
December 31, 2018 |
April 11, 2017 |
April 17, 2018 |
|
- StudyMetrix
Saint Peters, Missouri, United States - Clinvest Research, LLC
Springfield, Missouri, United States
|
| 37 |
NCT02784847 |
Not yet recruiting |
A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine |
|
|
Interventional |
Early Phase 1 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in monthly migraine days
- Change in mean attack severity
- Change in mean attack duration
- Number of patients who have at least a 50% reduction in monthly migraine days
|
10 |
Female |
18 Years to 65 Years (Adult) |
NCT02784847 |
UX007 |
TRIMI |
June 2016 |
November 2016 |
November 2016 |
May 27, 2016 |
May 27, 2016 |
|
|
| 38 |
NCT01687101 |
Completed
Has Results |
STOPAIN in the Treatment of a Single Migraine Attack |
|
- Drug: STOPAIN topical gel
|
Interventional |
Not Applicable |
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of STOPAIN in the Acute Treatment of Migraine
|
32 |
All |
18 Years to 65 Years (Adult) |
NCT01687101 |
SDS/STPAIN/01 |
|
May 2012 |
May 2013 |
May 2013 |
September 18, 2012 |
June 9, 2017 |
April 27, 2015 |
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 39 |
NCT01629329 |
Terminated |
Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine |
|
- Drug: Aspirin, Acetaminophen, Caffeine pills
- Drug: Prochlorperazine 10mg
|
Interventional |
Phase 4 |
- Albert Einstein Healthcare Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Mean difference from baseline of VAS pain scores
- Number of reported adverse side-effects
|
93 |
All |
18 Years to 65 Years (Adult) |
NCT01629329 |
4258 |
Migraine |
November 2010 |
April 2014 |
April 2014 |
June 27, 2012 |
June 25, 2014 |
|
- Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
|
| 40 |
NCT02991430 |
Recruiting |
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache |
|
- Device: active neuromodulation for episodic migraine headache
- Device: placebo neuromodulation for episodic migraine headache
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- change in migraine headache days (MHD)
- normalized reduction in migraine headache days
- change in medication usage
- (and 7 more...)
|
120 |
All |
18 Years to 65 Years (Adult) |
NCT02991430 |
SNS-MIG-02 |
|
June 30, 2017 |
July 2018 |
September 2018 |
December 13, 2016 |
October 31, 2017 |
|
- Mayo Clinic
Scottsdale, Arizona, United States - Neurology Research Institute
West Palm Beach, Florida, United States - Diamond Headache Clinic
Chicago, Illinois, United States - (and 7 more...)
|
| 41 |
NCT01924052 |
Completed |
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load |
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
|
- CGRP induced migraine attacks in patients with high and low genetic load
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT01924052 |
H-2-2011-141 |
|
June 2013 |
August 2013 |
August 2013 |
August 16, 2013 |
August 16, 2013 |
|
|
| 42 |
NCT02307071 |
Unknown † |
Occipital Transcutaneous Stimulation in Chronic Migraine |
|
- Device: Cefaly Kit Arnold
|
Interventional |
Phase 4 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Monthly frequency of migraine days
- Monthly frequency of headache days
- Monthly frequency of total headache days
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult) |
NCT02307071 |
OTSCM |
OSCRO |
November 2014 |
September 2015 |
December 2015 |
December 3, 2014 |
May 28, 2015 |
|
- CHR Citadelle
Liege, Belgium
|
| 43 |
NCT03217968 |
Completed |
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device |
|
- Device: Cefaly® Abortive Program device
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain Freedom (PF) at 2 hours
- Most bothersome migraine-associated symptom (MBS) freedom at 2 hours
- Pain Relief (PR) at 2 hours
- (and 3 more...)
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT03217968 |
50803 |
|
August 10, 2017 |
January 10, 2018 |
January 10, 2018 |
July 14, 2017 |
February 26, 2018 |
|
- Rochester Clinical Research, Inc.
Rochester, New York, United States
|
| 44 |
NCT03459495 |
Not yet recruiting |
Therapeutic Ultrasound in the Treatment of Migraine |
|
- Device: therapeutic ultrasound
- Device: placebo ultrasound
|
Interventional |
Not Applicable |
- Bursa Yüksek İhtisas Education and Research Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Numeric rating scale (NRS)
- Migraine Disability Assessment Questionnaire Score (MIDAS)
- paracetamol consumption
- the number of migraine attacks per month.
|
58 |
All |
20 Years to 65 Years (Adult) |
NCT03459495 |
2011-KAEK-2018-1/25 |
|
March 10, 2018 |
September 10, 2018 |
September 10, 2018 |
March 9, 2018 |
March 9, 2018 |
|
|
| 45 |
NCT01720862 |
Completed |
Migraine and Body Composition |
- Migraine With and Without Aura
- Chronic Migraine
- Healthy Controls
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- association between migraine and obesity - evaluate serum adipokine levels
- association between migraine and obesity -evaluate subcutaneous adipose tissue (SAT) and its ratio to visceral adipose tissue (VAT)
|
300 |
Female |
18 Years to 50 Years (Adult) |
NCT01720862 |
NA_00051683 |
|
April 2012 |
October 2015 |
October 2015 |
November 2, 2012 |
January 28, 2016 |
|
- The Johns Hopkins Bayview Headache Center
Baltimore, Maryland, United States
|
| 46 |
NCT01952574 |
Active, not recruiting |
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention |
|
- Drug: AMG 334
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in monthly migraine days from baseline in the last 4 weeks of the 12-week double-blind treatment phase
- Proportion of subjects with at least a 50% reduction from baseline in monthly migraine days in the last 4 weeks of the 12-week double-blind treatment phase
- Change in monthly migraine attacks from baseline in the last 4 weeks of the 12-week double-blind treatment phase
- Adverse events, clinical laboratory values, electrocardiogram, vital signs, anti-AMG 334 antibodies
|
483 |
All |
18 Years to 60 Years (Adult) |
NCT01952574 |
20120178 |
|
August 6, 2013 |
September 25, 2014 |
November 11, 2019 |
September 30, 2013 |
December 19, 2017 |
|
- Research Site
Phoenix, Arizona, United States - Research Site
Long Beach, California, United States - Research Site
National City, California, United States - (and 63 more...)
|
| 47 |
NCT02562196 |
Recruiting |
tDCS for the Treatment of Migraine |
|
|
Interventional |
Phase 2 |
- Universidade Federal de Pernambuco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in headache diary variables
- Changes on Visual Evoked Potentials measures
- Changes on HIT-6
- (and 5 more...)
|
14 |
All |
18 Years to 55 Years (Adult) |
NCT02562196 |
Effect_tDCS_Migraine |
|
March 2016 |
August 2016 |
April 2018 |
September 29, 2015 |
May 11, 2016 |
|
- Applied Neuroscience Laboratory
Recife, Pernambuco, Brazil
|
| 48 |
NCT01723514 |
Completed |
Ascending Multiple-Doses of AMG 334 in Healthy Subjects and in Migraine Patients |
|
- Drug: AMG 334
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs.
- The maximum observed concentration, time to maximum concentration and the area under the serum-concentration curve after multiple doses of AMG 334.
- The ratio of blood flow measure at 30 minute post capsaicin challenge to the flow measure prior to the capsaicin challenge.
|
48 |
All |
18 Years to 55 Years (Adult) |
NCT01723514 |
20101268 |
|
November 2012 |
July 2014 |
July 2014 |
November 8, 2012 |
July 28, 2014 |
|
- Research Site
Leuven, Belgium
|
| 49 |
NCT02764996 |
Completed |
An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine |
|
|
Interventional |
Not Applicable |
- Mike O'Callaghan Military Hospital
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Reduction of migraine headache pain
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT02764996 |
FWH20150084H |
|
December 2015 |
June 2017 |
June 2017 |
May 6, 2016 |
August 11, 2017 |
|
- Mike O'Callaghan Federal Medical Center
Nellis Air Force Base, Nevada, United States
|
| 50 |
NCT01688739 |
Completed |
Ascending Single Doses of AMG 334 in Healthy Subjects and Migraine Patients |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs.
- The number of subjects with anti-AMG 334 antibodies after a single dose of AMG 334.
- The maximum observed concentration, time to maximum concentration and the area under the serum-concentration curve after a single dose of AMG 334.
- The ratio of blood flow measure at 30 minute post capsaicin challenge to the blood flow measure prior to the capsaicin challenge.
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT01688739 |
20101267
2011-005600-15 |
|
March 13, 2012 |
May 1, 2013 |
|
September 20, 2012 |
November 6, 2017 |
|
- Research Site
Leuven, Belgium
|
Create an RSS feed from your search for:
Download the search results for: